Profound Medical Corp. marked a significant milestone on November 18, 2025, when Dr. Y. Mark Hong at The Hong Center Scottsdale completed the company’s 200th independent TULSA procedure. The procedure was performed entirely by a urologist, without radiologist involvement, demonstrating the feasibility of a urologist‑led workflow on the TULSA‑PRO system.
The milestone comes amid a broader trend of increasing urologist adoption of the TULSA‑PRO platform. In Q3 2025, Profound reported an 87% year‑over‑year revenue increase to $5.3 million, driven by a 74.3% gross‑margin expansion from 63.1% the previous year. The 200‑case count underscores the platform’s clinical uptake and supports the company’s strategy to expand beyond radiology‑driven practices.
Management highlighted the milestone’s clinical and commercial implications. CEO and Chairman Arun Menawat said the achievement “represents the hundreds of men who are now living cancer‑free, with preserved quality of life, thanks to Dr. Hong’s expertise.” He added that the independent workflow could accelerate market penetration by reducing the need for radiology departments and shortening site‑installation timelines.
The 200‑case benchmark also strengthens Profound’s position in reimbursement discussions. Real‑world evidence of safety, efficacy, and patient outcomes without additional specialist support provides a compelling case for payers to cover the TULSA‑PRO system, potentially expanding its adoption across the prostate disease spectrum.
Looking ahead, Profound’s Q3 2025 earnings signal continued momentum. The company’s gross‑margin growth reflects pricing power and operational leverage, while the 87% revenue rise indicates robust demand for incision‑free prostate therapy. The milestone reinforces the company’s competitive differentiation against traditional surgery and radiation, positioning TULSA‑PRO as a leading solution for prostate disease management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.